Netherlands· NL-7f63ae7bacf2
Renvela 0.8 g poeder voor orale suspensie
A sevelamer product containing sevelameercarbonaat 0-water, registered in Netherlands by Sanofi Winthrop Industrie. The same ATC class is registered in 18 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sevelamer is registered in 18 of 19 countries.
Countries holding a registration under ATC V03AE02 (sevelamer), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 11 of them publish a price we can compare per daily dose
Sevelamer · ATC V03AE02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sevelamer costs, country by country.
Normalised to the WHO defined daily dose (6.4 g), the median price runs from $3.42 in France to $9.10 in Switzerland — a ×2.7 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Sevelamer · price per daily dose (6.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$9.10
- ES Spain$6.97
- IT Italy$5.92
- US United States$5.56 (acquisition cost)
- FR France$3.42
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SEVELAMEERCARBONAAT 0-WATER
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Netherlands (NL)
- ATC code
- V03AE02
- ATC class
- Sevelamer
- Defined daily dose
- 6.4 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/09/521
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
293 interactions on record for sevelamer.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sevelamer · interactions on record
293 records
- 2 severe
- 31 moderate
- 258 info
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- ErgocalciferolA11CC01moderate
- DihydrotachysterolA11CC02moderate
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sevelamer in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandRenvelaSanofi Winthrop Industrie
- SpainRENVELA 0,8 G POLVO PARA SUSPENSION ORALSanofi Winthrop Industrie
- FranceRENVELA 0,8 g, poudre pour suspension buvableSANOFI WINTHROP INDUSTRIE
- United KingdomRenvela 0.8g oral powder sachetsSanofi
- ItalyRENAGEL*180 cpr rivestite 800 mg flaconeSANOFI WINTHROP INDUSTRIE
- IrelandRenagelSanofi Winthrop Industrie
- SwitzerlandRenagel, comprimés pelliculésSanofi-Aventis (Suisse) SA
- SwedenSevelamer Ebb 2,4 g Pulver till oral suspensionEbb Medical AB
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c1ac080-67ec-434e-9e97-d21191848914 GET /v1/drugs/9c1ac080-67ec-434e-9e97-d21191848914?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor orale suspensie",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/renvela-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sevelamer",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp122028",
"excipients": [
"CITROEN-LIMOENSMAAKSTOF",
"IJZEROXIDE GEEL (E 172)",
"NATRIUMCHLORIDE",
"PROPYLEENGLYCOLALGINAAT (E 405)",
"SINAASAPPEL-VANILLESMAAKSTOF",
"SUCRALOSE (E 955)",
"VANILLESMAAKSTOF"
],
"substances": [
"SEVELAMEERCARBONAAT 0-WATER"
],
"leaflet_url": null,
"authorised_at": "2009/06/10",
"procedure_number": "EMEA/H/C/000993",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/09/521",
"additional_monitoring": "N"
}See everything about sevelamer.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.